Zobrazeno 1 - 10
of 321
pro vyhledávání: '"Tian-Fu Wen"'
Autor:
Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4137-4146 (2023)
Abstract Objective This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background Pem
Externí odkaz:
https://doaj.org/article/33db6e2caae9409c859c394540b3696a
Autor:
Chang Liu, Lei Li, Wu-sheng Lu, Hua Du, Lu-nan Yan, Tian-fu Wen, Wu-ran Wei, Li Jiang, Ming-qing Xu
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background There is currently limited information regarding the prognostic ability of the dNLR-PNI (the combination of the derived neutrophil-to-lymphocyte ratio [dNLR] and prognostic nutritional index [PNI]) for hepatocellular carcinoma (HC
Externí odkaz:
https://doaj.org/article/a26a524f6428473fad36500135bffaaa
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0219219 (2019)
Posthepatectomy liver failure (PHLF) is the most leading cause of mortality following hepatectomy in patients with hepatocellular carcinoma (HCC). Platelet count was reported to be a simple but useful indicator of liver cirrhosis and function of sple
Externí odkaz:
https://doaj.org/article/449219c12e6441f99b6e0e5b6c181e4f
Publikováno v:
Chinese Medical Journal, Vol 129, Iss 5, Pp 536-541 (2016)
Background: The absolute lymphocyte counts (ALCs) have been reported as one of worse prognostic factors for hepatocellular carcinoma (HCC) patient after liver transplantation. The aim of this study was to assess the influence of ALCs on the outcomes
Externí odkaz:
https://doaj.org/article/dec8b7f3f66740148d5713d814f129fc
Autor:
Chuan Li, M.D., Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Ming-Qing Xu, Wen-Tao Wang, Yong-Gang Wei
Publikováno v:
Annals of Hepatology, Vol 11, Iss 4, Pp 471-477 (2012)
Background. Living donor liver transplantation (LDLT) for patients with high model for end-stage liver disease (MELD) scores is controversial due to its poor outcome. However, there is little information regarding which factor would negatively impact
Externí odkaz:
https://doaj.org/article/adade281221f4e5298bbf766df84360d
Autor:
Chuan Li, Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Ming-Qing Xu, Wen-Tao Wang, Yong-Gang Wei
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72235 (2013)
AIM: The selection criteria for patients with hepatocellular carcinoma (HCC) to undergo liver transplantation should accurately predict posttransplant recurrence while not denying potential beneficiaries. In the present study, we attempted to identif
Externí odkaz:
https://doaj.org/article/b1495fc3400e4bcda563c863d42b2586
Autor:
Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Publikováno v:
Cancer Medicine. 12:4137-4146
This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements.Pemigatinib provided clinical bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942046ddbca0aa5c7674c277496a9b51
https://doi.org/10.1002/cam4.5273
https://doi.org/10.1002/cam4.5273
Autor:
Yan‐Jun Xiang, Kang Wang, Hong‐Ming Yu, Miao‐Miao Wang, Le‐Qun Li, Hui‐Chuan Sun, Tian‐Fu Wen, Yu‐Qing Zhang, Yun‐Feng Shan, Li‐Ping Zhou, Shu‐Qun Cheng
Publikováno v:
Hepatology Research. 52:947-956
Surgical treatment is the first-line treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 or A1 hepatocellular carcinoma (HCC), and postoperative monitoring improves long-term survival. We aimed to establish a reasonable short-int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d9664a018a677ca1c547cf2c126908a
https://doi.org/10.1111/hepr.13811
https://doi.org/10.1111/hepr.13811
Publikováno v:
Scandinavian journal of gastroenterology.
Curative hepatectomy is currently the first-line treatment for hepatocellular carcinoma (HCC), but the prognosis is still not optimistic. The prediction model for prognosis of hepatitis B virus (HBV)-related BCLC 0-A stage HCC has not been well estab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f979395aa8dc3fc01fa03459592abfc
https://pubmed.ncbi.nlm.nih.gov/36620916
https://pubmed.ncbi.nlm.nih.gov/36620916
Autor:
Weili Qi, Chuan Li, Wei Peng, Junlong Dai, Shun Ran, Junyi Shen, Yu Zhang, Shusheng Leng, Tian-Fu Wen, Youwei Wu, Xiaoyun Zhang, Fengwei Gao
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8421-8431 (2021)
Cancer Medicine
Cancer Medicine
Background Antiviral therapy should reduce the recurrence of hepatitis B virus‐related hepatocellular carcinoma (HBV‐related HCC) after surgical resection. However, there is little research on whether various antiviral drugs have different progno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8351042c6fe66d43f560777096f72aa6
https://doaj.org/article/38c3395a483d4c26aa0047e582866ce7
https://doaj.org/article/38c3395a483d4c26aa0047e582866ce7